tirzepatide osa fda approval The has expanded the of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity — the first medication approved for the Breakthrough Treatment for Obstructive Sleep

This means that it helps healthy tissue heal but does not necessarily promote pathological growth

Some patients report feeling tired or having reduced energy levels, which may be related to changes in eating patterns or the direct effects of the medication on metabolism

Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the basal breast cancer subgroup

Those who let protein intake drop lost significant muscle mass alongside the fat, which undermines the metabolic benefits of weight loss

This process can compromise physical performance, slow down metabolism, and reduce overall resilience